Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
暂无分享，去创建一个
J. Jassem | A. Wardley | X. Pivot | F. Morales-Vásquez | C. Barton | A. Torres | L. Zetina | M. de Fátima Dias Gaui | D. Reyes | P. Button | V. Hersberger